Manufacturer record
Pharma Asia Drug 20-21: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Pharma Asia Drug 20-21 (Madhya Pradesh) was declared Not of Standard Quality in September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: PXD-16, Chlorhexidine Gluconate Solutions I.P. (exp Dec 2027). FDAL, Mumbai (state lab) found it not of standard quality: The content of chlorhexidine gluconate in the sample (i.e. 22.80 % of the stated amount) is less than the IP limit. (I.P. LIMIT ? 95 % TO. Listed in the September 2026 alert.
Records by type
1 record linked to Pharma Asia Drug 20-21 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Chlorhexidine Gluconate Solutions I.P. | Batch PXD-16Mfg Jan 2026 · Exp Dec 2027 | The content of chlorhexidine gluconate in the sample (i.e. 22.80 % of the stated amount) is less than the IP limit. (I.P. LIMIT ? 95 % TO 105 % of the stated amount) therefore, the drug is declared as misbranded vide rule 96, section 17 (b) of drugs and cosmetics act 1940 and rules 1945 thereunder.Misbranded | FDAL, MumbaiState lab | Sep 2026 |
Batches reported as suspected spurious under this label
CDSCO's spurious-drug alerts list batches that purport to be made by a company but are suspected counterfeits. The labelled manufacturer's reply is shown where CDSCO published it.
| Product | Batch | Reported by | Firm's reply | Alert |
|---|---|---|---|---|
| L-Carnitine, L- Tartarate ,Mecobalamin & Folic Acid Tablets | B95Y032 | SDTL, Assam | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | Apr 2026 |
| Trypsin-Chymotrypsin Tablets | 2KU6L055 | FDAL Maharashtra | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | Jan 2026 |
| Deflazacort Tablets 6 mg Defcort 6 | 13240334A | RDTL, Chandigarh | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | Dec 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.